Please be advised that updates to the Manufacturer Submission Policy were published effective April 1, 2015 and can be found at: https://idbl.ab.bluecross.ca/idbl/PDFS/dbl_sec1_drug.pdf
Should Manufacturers require additional clarification regarding the published Manufacturer Submission Policy please contact Alberta Blue Cross, Scientific and Research Services at: submissions@ab.bluecross.ca
For more information, please see ... Read More
News & Events
10
Apr2015
07
Apr2015
CADTH has posted its Guidelines for Manufacturers on Application Fees for the CADTH pan-Canadian Oncology Drug Review on its website, after stakeholder comments and feedback were received last month.
Key changes made in response to stakeholders’ comments are detailed in CADTH’s April 1, 2015 notice of implementation.
For ... Read More
30
Mar2015
We recently participated in Mediaplanet Canada’s Rare Diseases campaign in which many industry leaders united to provide Canadians with a comprehensive view of Canada’s healthcare system and the policies that affect the lives of those living with or affected by rare disorders. The campaign was distributed through the National Post on ... Read More
25
Mar2015
Effective April 1, 2015, the pCODR office will be moving to 154 University Avenue, Suite 300, Toronto from its current location at 1 University Ave, Suite 300. This move is to facilitate pCODR’s transition to CADTH while maintaining its central location in downtown Toronto.
Please note the new main telephone and fax ... Read More
25
Mar2015
PDCI is now offering a FREE TRIAL of its Canadian Drug Claims Database.
For those who are interested in the database and would like to learn more, this free trial gives registrants the opportunity to explore the database and test out its functionality at no cost!
For more information and to register, please ... Read More
12
Mar2015
Category 1 requirements for products that undergo a tailored CDR review have been revised. Submissions for new combination products (funded components) and new combination products designated by CADTH to undergo a tailored CDR review will require completion of the revised New Combination Product Submission Template. This revised template ... Read More
05
Mar2015
CADTH will be implementing an application fee for manufacturer applications filed with the pan-Canadian Oncology Drug Review (pCODR). The proposed fee will apply to all manufacturer applications with a Health Canada Notice of Compliance (NOC) or Notice of Compliance with Conditions (NOC/c) date of April 1, 2015 or later. The ... Read More
02
Mar2015
PDCI's pre-conference workshop at the upcoming Canadian Institute: Pharma Symposium Canada 2015 has been cancelled.
For those who may still be interested in the workshop, PDCI is more than happy to provide the workshop in the form of a Webinar or in-house training. Please contact Andrew Brooke for more information on ... Read More
23
Feb2015
Effective February 9, 2015 and until this process is transitioned to the pan-Canadian Pharmaceutical Alliance (pCPA) office, Saskatchewan will serve as the single point of entry for the pan-Canadian generic price tier confirmation process. The Saskatchewan Drug Plan will verify that the Tiered Pricing Framework applies to the ... Read More
04
Feb2015
Pilot Extension for Individual Patient Input to the Common Drug Review
The Common Drug Review (CDR) is extending its pilot to receive patient input submissions from individual patients and caregivers until August 3, 2015.
Pilot Extension for Patient Input for Therapeutic Reviews
CADTH implemented a pilot process for receiving patient input submissions for ... Read More